Skip to main content
SpringerLink
Log in

Augmentation strategies in resistant depression — some are effective and well tolerated

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schweitzer I, Tuckwell V. Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. Drug Saf 1998; 19(6): 455–64

    Article  PubMed  CAS  Google Scholar 

  2. Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry 2000; 61 (Suppl. 2): 13–9

    PubMed  Google Scholar 

  3. Mischoulon D, Nierenberg AA, Kizilbash L, et al. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry 2000 Jun; 45: 476–81

    PubMed  CAS  Google Scholar 

  4. Katona CLE, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80–6

    Article  PubMed  CAS  Google Scholar 

  5. Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307–14

    Article  PubMed  CAS  Google Scholar 

  6. Rosenbaum JF, Fava M, Nierenberg AA, et al. Treatment-resistant mood disorders. In: Gabbard GO, editor. Treatment of psychiatric disorders. 2nd ed. Washington DC: American Psychiatric Press, 1995: 1276–94

    Google Scholar 

  7. Hullet FJ, Bidder TG. Phenelzine plus triiodothyronine combination in a case of refractory depression. J Nerve MentDis 1983; 171: 318–20

    Article  Google Scholar 

  8. Stein D, Avni J. Thyroid hormones in the treatment of affective disorders. Acta Psychiatr Scand 1988; 7: 623–36

    Article  Google Scholar 

  9. Ereshefsky L. Drug-drug interactions involving antidepressant: focus on venlafaxine. J Clin Psychopharmacol 1996; 16: 37S–53S

    Article  PubMed  CAS  Google Scholar 

  10. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32: 1–21

    Article  PubMed  CAS  Google Scholar 

  11. Weilburg JB, Rosenbaum JF, Meltzer-Brody S, et al. Tricyclic augmentation of fluoxetine. Annal Clin Psychiatry 1991; 3: 209–13

    Article  Google Scholar 

  12. Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997; 12: 81–9

    Article  PubMed  CAS  Google Scholar 

  13. Perez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997 May 13; 349(9065): 1594–7

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Augmentation strategies in resistant depression — some are effective and well tolerated. Drugs Ther. Perspect 17, 6–9 (2001). https://doi.org/10.2165/00042310-200117050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117050-00002

Keywords

Search

Navigation